



CITY OF SOMERVILLE, MASSACHUSETTS
BICYCLE ADVISORY COMMITTEE

JOSEPH A. CURTATONE
MAYOR

MEMORANDUM

To: Omar Boukili, Mayor Curtatone's Office
From: Kathleen Ziegenfuss, Senior Planner, Transportation and Infrastructure
Re: Recommendation for Appointment to Somerville Bicycle Advisory Committee
Date: October 26, 2010

As the City liaison to the Somerville Bicycle Advisory Committee, I recommend that the Mayor and the Board of Aldermen appoint Ken Carlson to the Somerville Bicycle Advisory Committee. If appointed, Ken will fill a vacant position.

Attached please find a letter of interest from Ken Carlson as well as his resume.

Thank you for your attention to this matter. Please advise me of any progress on the status of this appointment.

221 Beacon St, #5
Somerville, MA 02143
October 24, 2010

The Honorable Mayor Joseph A. Curtatone
Somerville City Hall
93 Highland Avenue
Somerville, MA 02143

Dear Mayor Curtatone:

I am writing this letter to express my interest in becoming a member of the Somerville Bicycle Advisory Committee (SBAC). I am a relatively new resident of Somerville. My wife and I moved here in late January from West Windsor, New Jersey where we lived for 16 years. After arriving in Somerville, I soon learned about the SBAC and all that it has accomplished and was very interested in becoming involved. I have attended five of the monthly meetings and decided that I would very much like to officially join the Committee and offer my extensive experience in bicycle and pedestrian advocacy.

In addition to being a dedicated bicycle commuter and avid recreational cyclist, I have spent the last nine years devoted to bicycle and pedestrian advocacy. In 2006, I co-founded and was President of the West Windsor Bicycle and Pedestrian Alliance (www.wwbpa.org), a 501(c)3 devoted to improving the bikeability and walkability in the town where I lived. In just a few years, I led our organization in becoming one of the premier bicycle and pedestrian advocacy groups in the New Jersey. We brought in over one million dollars in state and federal grants, worked closely with our town's Mayor and Council, promoted education and awareness, and grew our membership to over 400 members. In the process we became widely known throughout the state and professional advocacy organizations, and served as a model for other towns. Our advocacy work was recognized by the NJ Department of Transportation in their quarterly newsletter where they published an extensive article on our organization and on my particular approach to advocacy (*NJ Walks and Bikes Vol 2, Issue 2* - http://policy.rutgers.edu/VTC/bikeped/Walks_and_Bikes/Vol2_Issue2/westwindsor1.html). Upon leaving West Windsor, I received a proclamation from the Mayor and Council for my years of dedication to bicycle and pedestrian advocacy.

Prior to founding the WWBPA, I was co-chairman of the Mayor's Bicycle and Pedestrian Task Force in our town for three years (2002 to 2005), a committee not unlike the SBAC where we worked closely with the Mayor to improve walking and biking in town. Prior to this appointment, I was co-chair of the Recreational Trails and Bikeways Committee, a sub-committee of the Friends of West Windsor Open Space (2001-2002). My sub-committee was responsible for developing strategies for developing trails both within and between preserved properties. In addition to my Bike-Ped work, I was also a Trustee of the Friends of West

Windsor Open Space, an organization whose mission was and is to preserve open space within the town.

As you can see, I am devoted bicycle and pedestrian advocate, and a person who likes to get very involved in the communities where I reside. I feel I could bring a lot to the SBAC from my many years of advocacy. I have already contributed ideas and shared my experiences at the SBAC meetings I have attended. Becoming a formal member will only increase my involvement and my desire to make Somerville a better place to live.

I look forward to your reply. I have enclosed my professional resume as well (I am currently Senior Director of Biology at Anchor Therapeutics, a start-up biotech located in East Cambridge). If you need to contact me, please do not hesitate to do so. I can be reached at 617-909-3150 and at kencarlson8@gmail.com.

Sincerely,

Kenneth E. Carlson

CC: Kathleen Ziegenfuss, Senior Planner, Transportation & Infrastructure

CURRICULUM VITAE

Kenneth Eugene Carlson

Business Address:

Anchor Therapeutics, Inc.
67 Rogers Street
Cambridge, MA 02142
Phone: 617-715-1982
FAX: 617-715-7906
Mobile : 617-909-3150
E-mail: kcarlson@anchortx.com

Education

- 1989** Ph.D. Pharmacology, University of Pennsylvania, Philadelphia, PA
Thesis: *Post-translational regulation of guanine nucleotide-binding proteins*
- 1984** M.A. (Accelerated combined B.A./M.A. Degree Program) Boston University, Boston, MA
Thesis: *Retrograde axonal transport of free glycine in identified neurons*
- 1983** B.A. *Magna cum laude* with distinction, Boston University, Boston, MA
Thesis: *Retrograde axonal transport of free glycine in the branchial nerve of Aplysia Californica*

Professional Experience

- 2009-present** Senior Director of Biology, Anchor Therapeutics. Department head of biology at a privately held biotechnology company, responsible for directing both *in vitro* and *in vivo* pharmacology departments. Member of senior leadership team.
- 2007-2009** Executive Director, Biological Sciences, Palatin Technologies. Department head of Biological Sciences at a mid-sized biotechnology company, responsible for directing both *in vitro* and *in vivo* pharmacology departments and co-chairing several drug discovery programs. Responsible for setting the direction of biology within the organization and for bringing forward IND candidates.
- 2005-2007** Senior Principal Scientist, Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute. Program co-chair of a drug discovery program, co-directing a 40-plus person multi-disciplinary discovery team. Active member of the Development Team for

SLV-319, a Phase IIb clinical candidate for Obesity that BMS is co-developing with Solvay Pharmaceuticals. In addition, Co-chair of two exploratory GPCR programs.

- 2003-2005** Principal Scientist, Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute. Biology co-chair of a drug discovery program, co-directing a 40-plus person multi-disciplinary discovery team. In addition, co-chair of an Institute-wide G protein Coupled Receptor Target Team with oversight responsibility for orphan receptor drug discovery, focused library development, and evaluation of technologies for in-licensing.
- 2000-2003** Senior Research Investigator-II, Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute. Biology co-chair of a Melanocortin Receptor-1 Agonist Program, co-directing a 10-plus person multi-disciplinary drug discovery team. In addition, co-chair of a company-wide G protein-Coupled Receptor Focused Group which fostered the sharing of GPCR knowledge and best practices across the Institute. Also served on the DuPont Pharmaceutical Integration Team during the acquisition of DuPont Pharma.
- 1997-2000** Senior Research Investigator-I, Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute. In vitro pharmacology co-leader of a Dual Endothelin/Angiotensin II Receptor Program for hypertension and heart failure. In addition, in vitro pharmacology/molecular biology co-leader of several chemokine receptor programs.
- 1993-1997** Research Investigator-II, Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute. Provided molecular and cell biology support to a Thrombin Receptor Program and molecular and pharmacology support to a chemokine receptor Program.
- 1991-1993** Staff Fellow, Hormone Action and Oncogenesis Section, Laboratory of Molecular Virology, National Cancer Institute, NIH, Bethesda, Maryland. Research focus: transcriptional control of the Mouse Mammary Tumor Virus Long Terminal Repeat.
- 1989-1991** PRAT Fellow (Pharmacology Research Associate Training Program, NIGMS), Hormone Action and Oncogenesis Section, Laboratory of Experimental Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland.

Personal Information

Date and Place of Birth	January 8, 1961; Perth Amboy, New Jersey
Marital Status	Married, 2 children

Performance Awards

2007 (Excellence Award, Stock Option Award, Restricted Stock Award)
2006 (Excellence Award, Stock Option Award, Restricted Stock Award)
2005 (Excellence Award, Stock Option Award)
2004 (Excellence Award, Stock Option Award)
2003 (Excellence Award, Stock Option Award, Triumph Award as Leader of GPCR Target Team)
2002 (Stock Option Award, DuPont Integration Award, Computer World Honors 21st Century Achievement Award, Triumph Award as Member of Target Validation Committee)
2001 (Stock Option Award)
1999 (Excellence Award)
1998 (Excellence Award)
1997 (Excellence Award)
1996 (Excellence Award)
1995 (Excellence Award)

Patents

US Provisional Patent Application No. 61/059,910; filed June 9, 2008 entitled Melanocortin Receptor-Specific Peptides for Treatment of Sexual Dysfunction

US Provisional Patent Application No. 61/038,800; filed March 24, 2008
Treatment of Circulatory Shock, Ischemia, Inflammatory Diseases and Related Conditions

US Provisional Patent Application HA0774 NP; filed 5/11/2001. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders.

Bibliography

- Kang, L. Flint, O., Moyer, C., Brannen, K., and **Carlson, K.** Off-Target Myotoxicity in Dogs Caused by a Cannabinoid-1 Receptor Antagonist. In preparation.
- Tchernerncychev, B., Ren, Y., Janz, J., Haggis, L. Qing D., Kazmi, M., Looby, R., McBride, E., McMurry, T., O'Shea, A., Sachdev, P., Sakmar, T., Hunt, S., **Carlson, K.** Discovery of a novel pepducin agonist of CXCR4. In review.
- Doree F. Sitkoff, Ning Lee, Bruce A. Ellsworth, Qi Huang, Liya Kang, RoseAnn Baska, Ying Wang, Yanting Huang, Chongqing Sun, Annapurna Pendri, Patti Reggio, William R. Ewing, Mary Ann Pelleymounter, **Kenneth E. Carlson.** Cannabinoid 1 (CB1) ligand binding and function examined through mutagenesis studies of F200 and S383. European J. of Pharm., in press.

- Leoni, Giovanna, Benoit-Voisin, Matthieu, **Carlson, Kenneth**, Getting, Stephen, Nourshargh, Sussan, and Perretti, Mauro. The MC1R agonist BMS-470539 inhibits leukocyte trafficking in the inflamed vasculature. *Brit. J. Pharm.* 160:171-180, 2010.
- Ellsworth, B., Wang, Y., Zhu, Y., Sun, C., **Carlson, K.E.**, Kang, L., Baska, R., Yang, Y., Huang, Q., Cullen, M., Johnghar, S., Behnia, K., Pelleymounter, M., Ewing, W.R. Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series. *Bioorganic Med. Chem. Lett.* 17 (14): 3978-3982, 2007.
- Kang, L., McIntyre, K., Gillooly, K., Yang, Y., Haycock, J., Roberts, S., Khanna, A., Herpin, T., Yu, G., Morton, G., Tuerdi, H., Koplowitz, B., Walker, S., Wardwell-Swanson, J., Macor, J., R. Lawrence, and **Carlson, K.** A Selective Small Molecule Agonist of the Melanocortin-1 Receptor Inhibits Lipopolysaccharide-induced Cytokine Accumulation and Leukocyte Infiltration in Mice. *J. Leuk. Biol.* 80:897-904, 2006.
- Katerinaki, E., Haycock, J., Lalla, R., **Carlson, K.**, Yang, Y., Hill, R., Lorigan, P., and McNeil, S. Sodium salicylate inhibits TNF- α induced NF- κ B activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. *Melanoma Research* 16:11-22, 2006.
- Kelly, J.M., Moir, A.J.G., **Carlson, K.**, Yang, Y., MacNeil, S., and Haycock, J. Immobilized α -Melanocyte Stimulating Hormone 10-13 (GKPV) Inhibits Tumour Necrosis factor- α Stimulated NF- κ B Activity. *Peptides* 27:431-437, 2006.
- Natesan Murugesan, Zhengxiang Gu, Leena Fadnis, John E. Tellew, Rose Ann F. Baska, Yifan Yang, Sophie M. Beyer, Hossain Monshizadegan, Kenneth E. Dickinson, Maria T. Valentine, Saeho Chong, William R. Ewing, **Kenneth E. Carlson**, Mark C. Kowala and John E. Macor. Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl biphenylsulfonamides with Improved Potency and Pharmacokinetics. 48: 171-179, 2005.
- Kowala, M.C., Murugesan, N., Tellew, J.E., **Carlson, K.E.**, Monshizadegan, H., Ryan, C., Gu, Z., Kane, B.L., Fadnis, L., Baska, R.F., Y. Yang, Beyer, S.M., Dickinson, Zang, D., Perrone, M., Ferrer, P., Giancarli, M., Bauman, J., Bird, E., Panchal, B., S. Arthur, Trippodo, N., Barrish, J., and Macor, J. Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension. *J. Pharmacol Exp Ther.* 309(1):275-84, 2004.
- Tellew, J.E., Baska, R.F., Beyer, S.M., **Carlson, K.E.**, Cornelius, L.A., Fadnis, L., Gu, Z., Kane, B.L., Kowala, M.C., Monshizadegan, H., Murugesan, N., Ryan, C.S., Valentine, Yang, Y., and Macor, J.E. Discovery of 4'-[(Imidazol-1-yl)methyl]biphenyl-2-sulfonamides as Dual Endothelin/Angiotensin II Receptor Antagonists. *Bioorg Med Chem Lett.* 13(6):1093-6, 2003.
- Herpin, T.F., Yu, G., **Carlson, K.E.**, Morton, G.C., Wu, X., Tuerdi, H., Khanna, A., Tokarski, J., Kang, L., Lawrence, R.M., Poss, M.A., Macor, J.E., Zahler, R.. Discovery of Potent and

Selective Melanocortin-1 Receptor (MC-1R) Small Molecule Agonists with Anti-inflammatory Properties. *J. Med. Chem.* 46: 1123-1126, 2003.

Murugesan, N., Tellew, J.E., Gu, Z., Kane, B.L., Fadnis, L., Cornelius, L.A., Baska, R.F., Yang, Y., Beyer, S.M., Monshizadegan, H., Dickinson, K., Panchal, B., Valentine, M.T., Chong, S., Morrison, R.A., **Carlson, K.E.**, Powell, J.R., Moreland, S., Barrish, J.C., Kowala, M.C., and Macor, J.E. Discovery of Potent Dual Angiotensin II and Endothelin A Receptor Antagonists. *J. Med. Chem.* 45:3829-3835, 2002.

Carlson K.E., Kusk P., Warren, B.S., and Hager G.H. Role of the TATA box in transcription of the MMTV LTR. *Mol. Endo.* 9:1180-1192, 1995.

Carlson K.E., Brass L.F., and Manning D.R. Selective phosphorylation of a G protein within permeabilized and intact platelets caused by activators of protein kinase C. In: **Biology of Cellular Transducing Signals**, Jack Y. Vanderhoek, ed. (Plenum Press) 1990: pp. 185-192.

Carlson K.E., Brass L.F., and Manning D.R. Thrombin and phorbol esters cause the selective phosphorylation of a G protein other than G_i in human platelets. *J. Biol. Chem.* 264: 13298-13305, 1989.

Wilde M.W., **Carlson K.E.**, Manning D.R., and Zigmond S.H. Chemoattractant-stimulated GTPase activity is decreased on membranes from polymorphonuclear leukocytes incubated in chemoattractant. *J. Biol. Chem.* 264: 190-196, 1989.

Mahy N., Woolkalis M.J., Thermos K., **Carlson K.**, Manning D., and Reisine T. Pertussis toxin modified the characteristics of both the inhibitory GTP-binding proteins and the somatostatin receptor in anterior pituitary tumor cells. *J. Pharmacol. Exp. Ther.* 246: 779-785, 1988.

Penning T.M., **Carlson K.E.**, and Sharp R.B. Affinity-labeling of the anti-inflammatory drug and prostaglandin binding site of 3 α -hydroxysteroid dehydrogenase of rat liver cytosol with 17 - and 21-bromoacetoxysteroids. *Biochem. J.* 245: 269-276, 1987.

Carlson K.E., Woolkalis M.J., and Manning D.R. Fractionation of the β g subunit common to guanine nucleotide-binding regulatory proteins with the cytoskeleton. *Mol. Pharmacol.* 30: 463-468, 1986.

Carlson K.E., Price C.H., and Aizenman E. Selective retrograde axonal transport of free glycine in identified neurons of Aplysia. *Cell. Mol. Neurobiol.* 3: 231-247, 1984.

Invited Talks

University of Pennsylvania, Department of Pharmacology- Peptides, an Inside Story,
09/27/2010

Keystone GPCR Conference, Breckenridge, CO- Identification of a Pepducin Agonist of the CXCR4 Receptor. 04/2010

Allosteric Modulator Conference, Philadelphia, PA.- Pepducins – A Novel Approach to Allosteric Modulation of G Protein-coupled Receptors. 01/2010

Pharmacopeia Inc.- Modulation of Inflammation by a Melanocortin-1 receptor small molecule agonist. 05/2003

Zengen Inc- Modulation of Inflammation by a Melanocortin-1 receptor small molecule agonist. 06/2003.

Professional Activities

Reviewer for the Journal of Pharmacology and Experimental Therapeutics

Ad hoc reviewer of NIH grant applications

Recent Meeting Abstracts

Gordon Conference Abstract

SBS 2010 Abstract

Discovery of BMS-812204, a cannabinoid receptor (CB1) antagonist, via reductions in log P in the series to balance volume of distribution and clearance. Bruce A. Ellsworth, Ximao Wu, Philip Sher, Gang Wu, Amarendra Mikkilineni, Zhengxiang Gu, Natesan Murugesan, Yeheng Zhu, Guixue Yu, Doree Sitkoff, **Kenneth E. Carlson**, Liya Kang, Yifan Yang, |Ning Lee, |Rose A. Baska, Qi Huang, William Keim, Mary Jane Cullen, Eva Zuvich, Michael Thomas, |Kenneth Rohrbach, James Devenny, |Helen Godonis, |Susan Harvey, |Brian Murphy, |Gerry Everlof, Paul Stetsko, Olafur Gudmundsson, Susan Johnghar, Asoka Ranasinghe, Kamelia Behnia, Mary Ann Pelleymounter, |William R. Ewing. ACS national Meeting, Washington D.C, 2009.

Discovery of di-aryl triazolopyridazine cannabinoid receptor (CB1) antagonists. Yu, Guixue; Ellsworth, Bruce A.; Mikkilineni, Amarendra; Wu, Ximao; Wang, Ying; Sitkoff, Doree; Gu, Zhengxiang; Murugesan, Natesan; Swartz, Steve; **Carlson, Kenneth**; Kang, Liya; Yang, Yifan; Lee, Ning; Baska, RoseAnn; Huang, Qi; Cullen, Mary Jane; Zuvich, Eva; Thomas, Michael; Rohrbach, Kenneth W.; Devenney, James; Godonis, Helen; Harvey, Susan; Johnghar, Susan; Behnia, Kamelia; Pelleymounter, MaryAnn; Ewing, William R. Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, 2008 (2008).

Is the CB1 Receptor Expressed in Skeletal and Cardiac Muscle? **Kenneth Carlson**, Liya Kang, Kimberly Brannen, Julie Panzica-Kelly, Laura Marthaler, Jeffrey Charlap, Carolyn Moyer,

Russell Gullo, Ruth Mulvey, William Achanzar, Oliver Flint, and Karen Augustine. International Cannabinoid Research Society Meeting, 2007.

Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series. Bruce A. Ellsworth, Ying Wang, Yeheng Zhu, Wei Meng, Annapurna Pendri, Samuel W. Gerritz, Chongqing Sun, **Kenneth E. Carlson**, Liya Kang, RoseAnn Baska, Yifan Yang, Qi Huang, Mary Jane Cullen, Susan Johnghar, Kamelia Behnia, Mary Ann Pelleymounter, William N. Washburn and William R. Ewing. American Chemical Society, 2007.

Synthesis and SAR of heteroaryl-fused piperidines as novel cannabinoid-1 receptor antagonists. Sun, Chongqing; Huang, Yanting; Sulsky, Richard; Zhu, Yeheng; Kang, Liya; Yang, Yifang; Baska, Rose Ann; Cullen, Mary Jane; Keim, William; Pelleymounter, Mary Ann; Stetsko, Paul; Gudmunsson, Olafur; Johnghar, Susan; Wu, Steven; Behnia, Kamelia; **Carlson, Kenneth E.**; Ewing, William R. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007 (2007),

Discovery and Structure Activity Relationships of Tetrahydroquinolines as Novel Cannabinoid-1 Receptor Antagonists. Sun, C., Sitkoff, D., Huang, Y., Zhou, Y., Gu, Zhengxiang, Natesan, M., Kang, L., Yang, Y., Baska R, Cullen, M., Pelleymounter, K., Behnia, K., Stetsko, P., Gudmundsson, O., Johnghar, S., Wu, S., **Carlson, K.**, and Ewing, W. American Chemical Society, San Francisco, 2006.

Metabolism driven pharmacokinetic optimization of dual inhibitors of Angiotensin 1 and Endothelin A receptors. Ewing, William R.; Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Zhu, Yeheng; Yu, Guixue; Wu, Xiamo; Cornelius, Lyndon; Mason, Helen; Zahler, Robert; Zhang, Donglu; Authur, Susan; Baska, Rose Ann; Monshizadegan, Hossain; Ryan, Carol; **Carlson, Kenneth**; Kowala, Mark; D'Arienzo, Celia; Zhang, Hongjian; Humphreys, William G.; Macor, John E. 232nd ACS National Meeting, San Francisco, Sept. 10-14, 2006.

Synthesis of a series of novel substituted amino isoxazoles and their utility in the discovery of a series of dual Angiotensin II and Endothelin A receptor antagonists. Ewing, William R.; Zhu, Yeheng; Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Wu, Ximao; Cornelius, Lyndon A.; Macor, John E.; Zahler, Robert; Kunst, Bridgette; Zhang, Donglu; Authur, Susan; Baska, Roseann; Monshizadegan, Hossain; Ryan, Carol; **Carlson, Kenneth**; Humphreys, William G.; Zhang, Hongjian; Yu, Guixue; Mason, Helen; Tellew, John; Kowala, Mark; D'Arienzo, Celia. Abstracts, 38th Middle Atlantic Regional Meeting of the American Chemical Society, Hershey, PA, United States, June 4-7 (2006).

Design, synthesis, and evaluation of a series of biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists (Part 2). Murugesan, Natesan; Gu, Zhengxiang; Tellew, John E.; Kane, Bridgette; Fadnis, Leena; Cornelius, Lyndon; Baska, Rose Ann; Beyer, Sophie; Monshizadegan, Hossain; Valentine, Maria; Chong, Saeho; Morrison, Richard A.; **Carlson, Kenneth**; Ewing, Rick; Kowala, Mark; Macor, John E. Discovery Chemistry and Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Institute,

Princeton, NJ, USA. Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003 (2003)

Synthesis and SAR of a series of N-Isoxazolyl Biphenylsulfonamides as potent dual Angiotensin II and Endothelin A receptor antagonists. Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Kane, Bridgette; Cornelius, Lyndon; Baska, Rose Ann; Beyer, Sophie; Monshizadegan, Hossain; Valentine, Maria; Chong, Saeho; Morrison, Richard A.; **Carlson, Kenneth**; Ewing, William R.; Kowala, Mark; Macor, John E.; Murugesan, Natesan. Discovery Chemistry and Metabolic and Cardiovascular Drug Discovery. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003).

Design, synthesis, and evaluation of a series of biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists (Part 1). Murugesan, Natesan; Gu, Zhengxiang; Tellew, John E.; Kane, Bridgette; Fadnis, Leena; Cornelius, Lyndon; Baska, Rose Ann; Beyer, Sophie; Monshizadegan, Hossain; Valentine, Maria; Chong, Saeho; Morrison, Richard A.; **Carlson, Kenneth**; Ewing, Rick; Kowala, Mark; Macor, John E. Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003 (2003)

SR141617A and energy balance in DIO rats. **K. Carlson**, M.A. Pelleymounter, M.J. Cullen, L.Kang, Y. Yang, and C-Q. Sun. International Cannabinoid Research Society Symposium, 2003.

SR141617A and energy balance in DIO rats. M.A. Pelleymounter, M.J. Cullen, **K. Carlson**, L.Kang, and C-Q. Sun. Keystone Symposia: Obesity: New Insights into Pathogenesis and Treatment, 2002.

Effects of the M3 antagonist, darafenicin, on food intake and body weight in two models of obesity. M.J. Cullen, M.A. Pelleymounter, D. Rotella, **K. Carlson**, and K. Behnia. Keystone Symposia: Obesity: New Insights into Pathogenesis and Treatment, 2002.

References Available Upon Request